The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study.
 
Li Zhang
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Akeso Biopharma; AstraZeneca; CHINA SHIYAO PHARMA; HenRui; Roche; Sichuan Biokin Pharmaceutical
Research Funding - Akeso Biopharma (Inst); AstraZeneca (Inst); BMS (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); QiLu Pharmaceutical (Inst); Sichuan Biokin Pharmaceutical, (Inst); Sichuan Kelun-Biotech Biopharmaceutical (Inst)
 
Wenfeng Fang
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Xiangjiao Meng
No Relationships to Disclose
 
Runxiang Yang
No Relationships to Disclose
 
Guanming Jiang
No Relationships to Disclose
 
Jiuwei Cui
No Relationships to Disclose
 
Lang He
No Relationships to Disclose
 
Peng Chen
No Relationships to Disclose
 
Wei Zheng
No Relationships to Disclose
 
Yanyan Xie
No Relationships to Disclose
 
Qiming Wang
No Relationships to Disclose
 
Jiacheng Yang
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Yina Diao
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Leadership - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Junyou Ge
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Leadership - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.